Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2002

01-01-2002 | Original Article

Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats

Authors: Merrill J. Egorin, Theodore F. Lagattuta, Deborah R. Hamburger, Joseph M. Covey, Kevin D. White, Steven M. Musser, Julie L. Eiseman

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2002

Login to get access
Metadata
Title
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats
Authors
Merrill J. Egorin
Theodore F. Lagattuta
Deborah R. Hamburger
Joseph M. Covey
Kevin D. White
Steven M. Musser
Julie L. Eiseman
Publication date
01-01-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-001-0380-8

Other articles of this Issue 1/2002

Cancer Chemotherapy and Pharmacology 1/2002 Go to the issue

Original Article

Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer

Original Article

A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation

Original Article

Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts

Original Article

Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice

Original Article

Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines

Original Article

Atypical pharmacokinetics and excretion of new platinum analogues in rodents
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits